

Vyacheslav Mareev

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5881970/publications.pdf>

Version: 2024-02-01

36
papers

9,699
citations

304602

22
h-index

189801

50
g-index

55
all docs

55
docs citations

55
times ranked

11402
citing authors

#	ARTICLE	IF	CITATIONS
1	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2014, 35, 3033-3080.	1.0	2,591
2	Rosuvastatin in Older Patients with Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2007, 357, 2248-2261.	13.9	1,330
3	EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. <i>European Heart Journal</i> , 2006, 27, 2725-2736.	1.0	1,063
4	Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. <i>European Heart Journal</i> , 2015, 36, 657-668.	1.0	902
5	Atrial fibrillation management: a prospective survey in ESC Member Countries. <i>European Heart Journal</i> , 2005, 26, 2422-2434.	1.0	770
6	Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2010, 362, 1477-1490.	13.9	588
7	The prevalence of abnormal glucose regulation in patients with coronary artery disease across EuropeThe Euro Heart Survey on diabetes and the heart. <i>European Heart Journal</i> , 2004, 25, 1880-1890.	1.0	532
8	Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2010, 362, 1463-1476.	13.9	430
9	Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. <i>Circulation</i> , 2010, 122, 597-602.	1.6	195
10	Management and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularization. <i>European Heart Journal</i> , 2005, 26, 1169-1179.	1.0	161
11	Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. <i>European Heart Journal</i> , 2009, 30, 3015-3026.	1.0	117
12	Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. <i>European Journal of Heart Failure</i> , 2006, 8, 591-598.	2.9	111
13	Coenzyme Q10, Rosuvastatin, and Clinical Outcomes in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1196-1204.	1.2	105
14	Prevalence of ECG abnormalities in an international survey of patients with suspected or confirmed heart failure at death or discharge. <i>European Journal of Heart Failure</i> , 2007, 9, 491-501.	2.9	91
15	Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups. <i>European Journal of Heart Failure</i> , 2013, 15, 947-959.	2.9	75
16	Role of diuretics, Å blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. <i>BMJ</i> , The, 2013, 347, f6745-f6745.	3.0	72
17	Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBISÅ€II) trial. <i>European Journal of Heart Failure</i> , 2010, 12, 607-616.	2.9	71
18	International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. <i>European Journal of Heart Failure</i> , 2014, 16, 614-624.	2.9	71

#	ARTICLE	IF	CITATIONS
19	Consensus of Russian experts on the evaluation of arterial stiffness in clinical practice. Cardiovascular Therapy and Prevention (Russian Federation), 2016, 15, 4-19.	0.4	56
20	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: <scp>GALACTICâ€HF</scp> baseline characteristics and comparison with contemporary clinical trials. European Journal of Heart Failure, 2020, 22, 2160-2171.	2.9	47
21	Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study. Kardiologiya, 2021, 61, 15-27.	0.3	41
22	Results of Open-Label non-Randomized Comparative Clinical Trial: â€œBromhexline and Spironolactone for Coronâ€virUs Infection requiring hospiTalization (BISCUIT). Kardiologiya, 2020, 60, 4-15.	0.3	20
23	The activated immune system and the reninâ€angiotensinâ€aldosterone system in congestive heart failure. Journal of Internal Medicine, 1998, 243, 93-98.	2.7	18
24	Evaluation of the Functional Status Questionnaire in Heart Failure: A Sub-study of the Second Cardiac Insufficiency Bisoprolol Survival Study (CIBIS-II). Cardiovascular Drugs and Therapy, 2011, 25, 77-85.	1.3	12
25	Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. American Heart Journal, 2006, 152, 500-508.	1.2	10
26	Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. European Heart Journal, 2022, 43, 2212-2220.	1.0	10
27	Oxidative stress in patients with chronic heart failure and type 2 diabetes mellitus. Bulletin of Experimental Biology and Medicine, 2007, 143, 207-209.	0.3	9
28	Anaphylatoxins in dilated cardiomyopathy. Journal of Internal Medicine, 1993, 234, 139-142.	2.7	7
29	Coenzyme Q-10 in the treatment of patients with chronic heart failure and reduced left ventricular ejection fraction: systematic review and meta-analysis. Kardiologiya, 2022, 62, 3-14.	0.3	5
30	Iron deficiency in Russia heart failure patients. Observational cross-sectional multicenter study. Kardiologiya, 2022, 62, 4-8.	0.3	3
31	ESSENTIAL â€ The Studies of Oral Enoximone Therapy in Advanced Heart Failure. Journal of Cardiac Failure, 2005, 11, 721.	0.7	2
32	INFLUENCE OF PSYCHOEMOTIONAL DISORDERS ON THE EFFECTIVENESS OF EDUCATION AND ACTIVE OUTPATIENT CONTROL IN HEART FAILURE PATIENTS. Russian Journal of Cardiology, 2016, , 48-52.	0.4	2
33	PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION. Rational Pharmacotherapy in Cardiology, 2012, 8, 37-44.	0.3	1
34	Integrative respiratory and skeletal musculature training in patients with functional class IIâ€IV chronic heart failure and low or intermediate left ventricular ejection fraction: Design and rationale. Siberian Medical Journal, 2020, 35, 123-130.	0.3	1
35	Euvolemia as a criterion of diuretic therapy efficacy in chronic heart failure: Literature review. Siberian Medical Journal, 2020, 35, 13-25.	0.3	1
36	Response to Letter Regarding Article, â€œPathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Bothâ€ Circulation, 2011, 123, .	1.6	0